Published in Transplantation on March 27, 2011
Evidence for kidney rejection after combined bone marrow and renal transplantation despite ongoing whole-blood chimerism in rhesus macaques. Am J Transplant (2012) 1.54
Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant (2014) 1.49
CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. J Mol Cell Biol (2011) 1.45
Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction. Semin Immunol (2011) 1.21
Emerging concepts in haematopoietic cell transplantation. Nat Rev Immunol (2012) 1.20
Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism. Curr Opin Organ Transplant (2011) 1.10
Induction of tolerance through mixed chimerism. Cold Spring Harb Perspect Med (2014) 0.97
Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol (2011) 0.95
Translating tolerogenic therapies to the clinic - where do we stand? Front Immunol (2012) 0.91
Tolerogenic therapies in transplantation. Front Immunol (2012) 0.88
Transplantation tolerance: from theory to clinic. Immunol Rev (2014) 0.88
Transplantation tolerance and its outcome during infections and inflammation. Immunol Rev (2014) 0.86
Chimerism-based tolerance in organ transplantation: preclinical and clinical studies. Clin Exp Immunol (2017) 0.84
Long-term tolerance to kidney allografts after induced rejection of donor hematopoietic chimerism in a preclinical canine model. Transplantation (2012) 0.84
An act of tolerance. Nat Med (2012) 0.84
Mixed chimerism and split tolerance: mechanisms and clinical correlations. Chimerism (2012) 0.83
Naturally acquired microchimerism: implications for transplantation outcome and novel methodologies for detection. Chimerism (2014) 0.80
Clinical transplantation and tolerance: are we there yet? Int J Organ Transplant Med (2014) 0.79
Prospects for therapeutic tolerance in humans. Curr Opin Rheumatol (2014) 0.78
Use of hematopoietic cell transplants to achieve tolerance in patients with solid organ transplants. Blood (2016) 0.77
Immune tolerance in recipients of combined haploidentical bone marrow and kidney transplantation. Bone Marrow Transplant (2015) 0.76
Transplantation: moving to the next level. Immunol Rev (2014) 0.75
Global scientific vision with local vigilance: renal transplantation in developing countries. Nephrourol Mon (2014) 0.75
Combined Bone Marrow and Kidney Transplantation for the Induction of Specific Tolerance. Adv Hematol (2016) 0.75
Tolerance--is it worth it? Cold Spring Harb Perspect Med (2014) 0.75
Kidney Transplantation in Patients With Active Multiple Myeloma: Case Reports. Transplant Direct (2017) 0.75
HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42
Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant (2006) 3.34
Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med (1989) 3.34
Molecular characterisation of a hypervariable region downstream of the human alpha-globin gene cluster. EMBO J (1986) 2.77
Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet (1999) 2.26
Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation (1999) 2.16
Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation (1997) 1.45
Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant (2000) 1.33
Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant (1999) 1.28
Anti-tumour response despite loss of donor chimaerism in patients treated with non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol (2005) 1.22
Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen. Peripheral mechanisms do not contribute to maintenance of tolerance. Transplantation (1996) 1.18
Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med (1988) 1.17
Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism. Transplantation (2003) 1.12
Strategy to detect chimerism in allogeneic bone marrow transplant recipients by PCR-amplification fragment length polymorphism analysis of microsatellite polymorphisms. Vox Sang (1995) 1.10
Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance. Biol Blood Marrow Transplant (2001) 1.08
Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Exp Hematol (2007) 1.07
Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation. Exp Hematol (2006) 1.01
Role of indirect allo- and autoreactivity in anti-tumor responses induced by recipient leukocyte infusions (RLI) in mixed chimeras prepared with nonmyeloablative conditioning. Clin Immunol (2006) 0.88
HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med (2008) 7.42
Strategies to improve long-term outcomes after renal transplantation. N Engl J Med (2002) 6.76
Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant (2009) 6.22
Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant (2009) 4.33
Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med (2004) 3.58
Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant (2007) 3.58
Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity (2012) 3.21
Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol (2009) 2.70
Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations. Proc Natl Acad Sci U S A (2004) 2.54
Public stem cell banks: considerations of justice in stem cell research and therapy. Hastings Cent Rep (2004) 2.53
Clinical trial of islet xenotransplantation in Mexico. Xenotransplantation (2006) 2.51
CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant (2004) 2.45
In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature (2011) 2.44
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood (2011) 2.41
Organ transplantation--how much of the promise has been realized? Nat Med (2005) 2.26
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
Open letter to Xi Jinping, President of the People's Republic of China: China's fight against corruption in organ transplantation. Transplantation (2014) 2.11
Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant (2011) 2.11
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Host alloreactive memory T cells influence tolerance to kidney allografts in nonhuman primates. Sci Transl Med (2011) 1.97
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood (2013) 1.95
An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med (2006) 1.94
Tolerance induction in clinical transplantation. Transpl Immunol (2004) 1.90
Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant (2007) 1.89
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood (2010) 1.88
Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol (2004) 1.87
Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol (2002) 1.84
Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation (2004) 1.82
Xenotransplantation: current status and a perspective on the future. Nat Rev Immunol (2007) 1.80
Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages. Proc Natl Acad Sci U S A (2007) 1.80
Thrombotic microangiopathic glomerulopathy in human decay accelerating factor-transgenic swine-to-baboon kidney xenografts. J Am Soc Nephrol (2005) 1.79
Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res (2013) 1.75
Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation (2002) 1.75
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant (2012) 1.74
Will the pig solve the transplantation backlog? Annu Rev Med (2002) 1.74
Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int (2011) 1.73
Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood (2013) 1.72
Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int (2002) 1.72
Biology of desmoplastic melanoma: a case-control comparison with other melanomas. J Clin Oncol (2005) 1.71
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant (2008) 1.67
Local irradiation enhances congenic donor pluripotent hematopoietic stem cell engraftment similarly in irradiated and nonirradiated sites. Blood (2003) 1.64
In utero or ex utero cord blood collection: which is better? Transfusion (2002) 1.64
Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant (2011) 1.62
Antigen-specific human T-cell responses and T cell-dependent production of human antibodies in a humanized mouse model. Blood (2008) 1.60
alpha1,3-Galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching 6 months. Transplantation (2005) 1.56
Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B. Atherosclerosis (2011) 1.55
Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation. Am J Transplant (2004) 1.54
Liver transplantation for malignancy. Oncologist (2005) 1.54
Reproduction and transplantation: report on the AST Consensus Conference on Reproductive Issues and Transplantation. Am J Transplant (2005) 1.52
CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis. Leuk Lymphoma (2012) 1.52
Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations. Am J Transplant (2011) 1.51
Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance. Liver Transpl (2008) 1.50
Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant (2006) 1.49
The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood (2002) 1.49
Xenogeneic thymus transplantation in a pig-to-baboon model. Transplantation (2003) 1.47
Clinical role of the renal transplant biopsy. Nat Rev Nephrol (2012) 1.46
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma (2012) 1.45
Attenuation of phagocytosis of xenogeneic cells by manipulating CD47. Blood (2006) 1.44
Immunogenicity of umbilical cord tissue derived cells. Blood (2007) 1.42
The expanding frontier of hematopoietic cell transplantation. Cytometry B Clin Cytom (2012) 1.42
A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation (2003) 1.41
Phenotype, distribution and alloreactive properties of memory T cells from cynomolgus monkeys. Am J Transplant (2010) 1.39
A mouse B-cell alloantigen determined by gene(s) linked to the major histocompatibility complex. The Journal of Experimental Medicine. 1973. 138: 1289-1304. J Immunol (2011) 1.39
The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood (2007) 1.37
Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation (2003) 1.36
Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Am J Pathol (2008) 1.36
Identification of exogenous forms of human-tropic porcine endogenous retrovirus in miniature Swine. J Virol (2004) 1.35
Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. Biol Blood Marrow Transplant (2003) 1.35
Peritoneal cavity B cells are precursors of splenic IgM natural antibody-producing cells. J Immunol (2003) 1.34
Histocompatible miniature swine: an inbred large-animal model. Transplantation (2003) 1.33
Promotion of altruistic donation. Transplantation (2009) 1.33
Regulation of human short-term repopulating cell (STRC) engraftment in NOD/SCID mice by host CD122+ cells. Exp Hematol (2003) 1.30